CAR-T cell therapy: ICANS
Evidence-based neurology checklist on car-t cell therapy: icans: Onset and severity This is immune receptor cell associated neurotoxicity syndrome The onset is usually around day 5 of infusion The onset may however be delayed for up to three weeks It is graded 1-4 in severity Possible risk factors…
Onset and severity
- This is immune receptor cell associated neurotoxicity syndrome
- The onset is usually around day 5 of infusion
- The onset may however be delayed for up to three weeks
- It is graded 1-4 in severity
Possible risk factors
Clinical features
Language features
Magnetic resonance imaging (MRI) brain: features
Electroencephalogram (EEG): features
Steroid therapy
Other therapy
References
- Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020 (Online ahead of print).
- Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020; 4:3943-3951.
- Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol 2019; 37(Suppl 1):48-52.
- Pensato U, Amore G, D'Angelo R, et al. Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity. J Neurol 2021 (Online ahead of print).
- Beuchat I, Danish H, Rubin DB, et al. EEG findings in CART T associated neurotoxicity: clinical and radiological correlations. Neuro Oncol 2022; 24:313-325.
- And 1 more. Subscribe to see the full list
